These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17185626)

  • 1. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes.
    Miura J; Yamamoto Y; Osawa M; Watanabe T; Yonekura H; Uchigata Y; Yamamoto H; Iwamoto Y
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):253-4. PubMed ID: 17185626
    [No Abstract]   [Full Text] [Related]  

  • 2. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
    Misselwitz J; Franke S; Kauf E; John U; Stein G
    Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control.
    Neumann T; Lodes S; Kästner B; Franke S; Kiehntopf M; Lehmann T; Müller UA; Wolf G; Sämann A
    Osteoporos Int; 2014 May; 25(5):1527-33. PubMed ID: 24599273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency.
    Schiel R; Franke S; Busch M; Müller A; Fleck C; Müller UA; Braun A; Stein G
    Eur J Med Res; 2003 Jul; 8(7):283-91. PubMed ID: 12911864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
    Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
    Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pentosidine: a new biomarker in diabetes mellitus complications].
    Morales S; García-Salcedo JA; Muñoz-Torres M
    Med Clin (Barc); 2011 Mar; 136(7):298-302. PubMed ID: 20226481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
    Aubert CE; Michel PL; Gillery P; Jaisson S; Fonfrede M; Morel F; Hartemann A; Bourron O
    Diabetes Metab Res Rev; 2014 Nov; 30(8):679-85. PubMed ID: 24449227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.
    Yamamoto M; Yamaguchi T; Yamauchi M; Sugimoto T
    Diabetes Care; 2009 Dec; 32(12):2263-8. PubMed ID: 19752174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis.
    Hein G; Wiegand R; Lehmann G; Stein G; Franke S
    Rheumatology (Oxford); 2003 Oct; 42(10):1242-6. PubMed ID: 12777635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.
    Yoshida N; Okumura K; Aso Y
    Metabolism; 2005 Mar; 54(3):345-50. PubMed ID: 15736112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Müller UA; Stein G
    Eur J Med Res; 2004 Aug; 9(8):391-9. PubMed ID: 15337629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple non-invasive assessment of advanced glycation endproduct accumulation.
    Meerwaldt R; Graaff R; Oomen PHN; Links TP; Jager JJ; Alderson NL; Thorpe SR; Baynes JW; Gans ROB; Smit AJ
    Diabetologia; 2004 Jul; 47(7):1324-1330. PubMed ID: 15243705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study.
    Linssen PB; Henry RM; Schalkwijk CG; Dekker JM; Nijpels G; Brunner-La Rocca HP; Stehouwer CD
    Diab Vasc Dis Res; 2016 Jul; 13(4):278-85. PubMed ID: 27190078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.